Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Brodalumab for severe hidradenitis suppurativa: a case of clinico-radiologic improvement and literature review
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 34, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2023-10-16
DOI
10.1080/09546634.2023.2270091
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
- (2023) Alexa B Kimball et al. LANCET
- Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic
- (2023) Niamh Kearney et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- IL‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum
- (2022) Kristina Navrazhina et al. BRITISH JOURNAL OF DERMATOLOGY
- Long‐standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases
- (2021) Yasuyuki Yoshida et al. JOURNAL OF DERMATOLOGY
- Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review
- (2021) Nadia Kashetsky et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
- (2021) Sophie Glatt et al. JAMA Dermatology
- Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti‐TNF failure
- (2020) Monika Arenbergerova et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- The Effect of Subcutaneous Brodalumab upon Clinical Disease Activity in Hidradenitis Suppurativa: An Open Label Cohort Study
- (2020) John W. Frew et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Weekly Administration of Brodalumab in Hidradenitis Suppurativa: An Open Label Cohort Study
- (2020) J.W. Frew et al. BRITISH JOURNAL OF DERMATOLOGY
- A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance
- (2020) John W. Frew et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction
- (2018) Ellen Witte-Händel et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents
- (2017) Łukasz Matusiak et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa
- (2016) Alexa B. Kimball et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
- (2011) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More